Mª Dolores García Malo

Baptista MJ, Granada I, Morgades M, Calasanz MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortuño F, Garcia-Malo MD, Piñan MÁ, Oliveira AC, Talavera M, Buño I, Batlle-López A, Moreno C, Ferra C, Solé F. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. Am J Hematol. 2017 Jul;92(7):E132-E135. doi: 10.1002/ajh.24754. Epub 2017 Jun 1. PubMed PMID: 28383114.

AÑO: 2017; IF: 5.303

28383114

Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15. PubMed PMID: 28903342; PubMed Central PMCID: PMC5589581.

AÑO: 2017; IF: 5.168

28903342

Fernández-Caballero M, Salmerón D, Dolores Chirlaque M, Chen-Liang TH, Hurtado AM, García Malo MD, Ortuño FJ, Roldán V, Vicente V, Jerez A, De Arriba F. Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest. 2019 Feb;49(2):e13050. doi: 10.1111/eci.13050. Epub 2018 Dec 7. PubMed PMID: 30422316.

AÑO: 2019; IF: 3.481

30422316

Chen-Liang TH, Casado-Prieto AM, Campos-Rodríguez V, Hurtado AM, Amigo ML, García-Malo MD, Vicente V, Ortuño FJ, Jerez A. An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups. Int J Lab Hematol. 2018 May 18. doi: 10.1111/ijlh.12860. [Epub ahead of print] PubMed PMID: 29774987.

AÑO: 2018; IF: 2.073

29774987

García-Marco JA, Jiménez JL, Recasens V, Zarzoso MF, González-Barca E, De Marcos NS, Ramírez MJ, Parraga FJP, Yañez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernández IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Díaz MG, Ferrer S, Carbonell F, García-Vela JA; GELLC Study Group. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. PubMed PMID: 30890600; PubMed Central PMCID: PMC6821631.

AÑO: 2019; IF: 7.116

30890600